Boston Scientific apparently knows a good bet when it sees one. | That includes treating more than 200,000 patients with the ...

The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD ...

Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...

Atrial fibrillation (AFib) is the most common form of irregular heartbeat (arrhythmia). People with AFib have many treatment options, including medications and medical procedures. However ...

Proactively managing atrial fibrillation is crucial for patients and healthcare providers, often necessitating the use of drugs due to the condition's propensity for severe consequences ...

A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure.

A new study suggests that certain substances in the blood may help identify people with a type of irregular heartbeat called ...

Discover how abelacimab reduces bleeding risks in AFib patients by effectively lowering free factor XI levels.

Doylestown Health is broadening its treatment options for atrial fibrillation patients with a revolutionary system that ...

(MENAFN- GlobeNewsWire - Nasdaq) The global atrial fibrillation drugs market size was valued at USD 24.59 billion in 2024 and is projected to reach from USD 27 billion in 2025 to USD 62.64 billion ...